Nightstar Therapeutics Ltd. (NITE) Announces September 29th IPO
Nightstar Therapeutics Ltd. has a market-cap of $393.4 million.
Jefferies, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO and Wedbush PacGrow and Chardan were co-managers.
Nightstar Therapeutics Ltd. provided the following description of their company for its IPO: “We are a leading clinical-stage gene therapy company focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness. Leveraging our expertise in ophthalmology, gene therapy and drug development, we are developing a pipeline of proprietary product candidates that are designed to substantially modify or halt the progression of inherited retinal diseases for which there are no currently approved treatments. “.
Nightstar Therapeutics Ltd. was founded in 2013 and has 23 employees. The company is located at 215 Euston Road, London NW1 2BE, United Kingdom and can be reached via phone at +44 20 7611 2077 or on the web at http://www.nightstartx.com.
Receive News & Ratings for Nightstar Therapeutics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nightstar Therapeutics Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.